DCM
MREO

Driehaus Capital Management’s Mereo BioPharma MREO Stock Holding History

Driehaus Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-250,000
Closed -$765K – 426
2020
Q2 		$765K Buy
+250,000
New +$441K 0.02% 298

Other funds holding MREO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Driehaus Capital Management's MREO Position: Q3 2020 in Review

Driehaus Capital Management sold out of Mereo BioPharma (MREO) in Q3 2020, closing a stake of 250,000 shares — an estimated $765K sold.

Driehaus Capital Management first reported a position in MREO in Q2 2020 and held it in 1 quarter. The position peaked at $765K in Q2 2020. 28 funds tracked by Wall St. Rank hold MREO as of Q3 2020.

  • Driehaus Capital Management reported no remaining Mereo BioPharma position as of Q3 2020 after selling out during the quarter.
  • Driehaus Capital Management sold 250,000 Mereo BioPharma shares in Q3 2020, an estimated $765K.
  • Driehaus Capital Management first reported a position in Mereo BioPharma in Q2 2020 and held it in 1 quarter.
  • Driehaus Capital Management's Mereo BioPharma position peaked at $765K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2020.

Based on Driehaus Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.